Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient

Journal of the Neurological Sciences

Volumn 346, Issue 1-2, 2014, Pages 366-367

  Safouris, Apostolos ^a   Demulder, Anne ^a   Triantafyllou, Nikos ^b   Tsivgoulis, Georgios ^c,d  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; RIVAROXABAN; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

AGED; ANTICOAGULATION; AREA UNDER THE CURVE; BODY WEIGHT; BRAIN ISCHEMIA; CASE REPORT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LETTER; MALE; OBESITY; STROKE PATIENT; ANALOGS AND DERIVATIVES; STROKE;

AGED; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MALE; MORPHOLINES; STROKE; THIOPHENES;

EID: 84910150600     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.09.008     Document Type: Letter

References (10)

1. L. Breuer, J. Ringwald, S. Schwab, and M. Köhrmann Ischemic stroke in an obese patient receiving dabigatran N Engl J Med 368 2013 2440 2442
2. J. Stangier, and M. Feuring Using the Hemoclot direct thrombin inhibitor assay to determine plasma concentrations of dabigatran Blood Coagul Fibrinolysis 23 2012 138 143
3. Pradaxa emergency guide Accessed August 20, 2014 at http://www.boehringer-ingelheim.com/content/dam/internet/pm/pradaxaglobal/com-EN/documents/pdf/22710067-3%20Emergency%20Guide.pdf
4. J. Douxfils, A. Tamigniau, B. Chatelain, C. Chatelain, P. Wallemacq, and J.M. Dogné Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban Thromb Haemost 110 2013 723 731
5. J.P. Patel, L.N. Roberts, and R. Arya Anticoagulating obese patients in the modern era Br J Haematol 155 2011 137 149
6. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects J Clin Pharmacol 47 2007 218 226
7. A. Chagnac, T. Weinstein, A. Korzets, E. Ramadan, J. Hirsch, and U. Gafter Glomerular hemodynamics in severe obesity Am J Physiol Renal Physiol 278 2000 F817 F822
8. H.R. Buller, A.W. Lensing, M.H. Prins, G. Agnelli, A. Cohen, and A.S. Gallus A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study Blood 112 2008 2242 2247
9. P.A. Reilly, T. Lehr, S. Haertter, S.J. Connolly, S. Yusuf, and J.W. Eikelboom The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) J Am Coll Cardiol 63 2014 321 328
10. T.J. Moore, M.R. Cohen, and D.R. Mattison Dabigatran, bleeding, and the regulators BMJ 349 2014 g4517